Kala Bio to Ship First AI Agent in 14 Days, Tackles $180B Healthcare AI Market
Kala Bio will ship its first commercial AI agent from its Researgency.ai platform in approximately 14 days, marking its transition from clinical-stage biotech to a dual-engine model. The purpose-built AI platform targets the $180+ billion AI-in-healthcare market with automated workflows for research, compliance and clinical trials.
1. Platform Rebrand and Launch
Kala Bio completed the full rebrand of its Researgency.ai platform, which is now live and ready for enterprise clients. The platform provides a secure, auditable environment designed for pharma-grade compliance and serves as an operating system for bespoke AI agents in biotech workflows.
2. First AI Agent Deployment
The company is building its first custom AI agent with delivery expected in approximately 14 days. This go-to-market readiness marks Kala Bio’s shift from strategy to execution, with its scientists collaborating alongside AI engineers to deploy purpose-built agents.
3. Dual-Engine Growth Strategy
Kala Bio is evolving from a single-drug clinical-stage biotech into a dual-engine company combining a proprietary biologics pipeline with a scalable AI platform-as-a-service. This model aims to generate recurring revenue from enterprise subscriptions while advancing orphan drug and Fast Track programs.
4. Market Opportunity and Use Cases
The global AI-in-healthcare market is projected to exceed $180 billion by 2030, and Kala Bio is focused on three major pain points: repetitive workflows, regulatory documentation and trial consistency checks. Key use cases include research intelligence, clinical trial protocol drafting, regulatory submissions and safety monitoring agents.